Gebretekle Gebremedhin Beedemariam, Haile Mariam Damen, Abebe Taye Workeabeba, Mulu Fentie Atalay, Amogne Degu Wondwossen, Alemayehu Tinsae, Beyene Temesgen, Libman Michael, Gedif Fenta Teferi, Yansouni Cedric P, Semret Makeda
School of Pharmacy, Addis Ababa University, Addis Ababa, Ethiopia.
School of Public Health, Addis Ababa University, Addis Ababa, Ethiopia.
Front Public Health. 2020 Apr 9;8:109. doi: 10.3389/fpubh.2020.00109. eCollection 2020.
Intense antibiotic consumption in Low- and Middle-Income Countries (LMICs) is fueled by critical gaps in laboratory infrastructure and entrenched syndromic management of infectious syndromes. Few data inform the achievability and impact of antimicrobial stewardship interventions, particularly in Sub-Saharan Africa. Our goal was to demonstrate the feasibility of a pharmacist-led laboratory-supported intervention at Tikur Anbessa Specialized Hospital in Addis Ababa, Ethiopia, and report on antimicrobial use and clinical outcomes associated with the intervention. This was a single-center prospective quasi-experimental study conducted in two phases: (i) an intervention phase (November 2017 to August 2018), during which we implemented weekly audit and immediate (verbal and written) feedback sessions on antibiotic prescriptions of patients admitted in 2 pediatric and 2 adult medicine wards, and (ii) a post-intervention phase (September 2018 to January 2019) during which we audited antibiotic prescriptions but provided no feedback to the treating teams. The intervention was conducted by an AMS team consisting of 4 clinical pharmacists (one trained in AMS) and one ID specialist. Our primary outcome was antimicrobial utilization (measured as days of therapy (DOT) per 1,000 patient-days and duration of antibiotic treatment courses); secondary outcomes were length of hospital stay and in-hospital all-cause mortality. A multivariable logistic regression model was used to explore factors associated with all-cause in-hospital mortality. We collected data on 1,109 individual patients (707 during the intervention and 402 in the post-intervention periods). Ceftriaxone, vancomycin, cefepime, meropenem, and metronidazole were the most commonly prescribed antibiotics; 96% of the recommendations made by the AMS team were accepted. The AMS team recommended to discontinue antibiotic therapy in 54% of cases during the intervention period. Once the intervention ceased, total antimicrobial use increased by 51.6% and mean duration of treatment by 4.1 days/patient. Mean LOS stay as well as crude mortality also increased significantly in the post-intervention phase (LOS: 24.1 days vs. 19.8 days; in hospital death 14.7 vs. 6.9%). The difference in mortality remained significant after adjusting for potential confounders. A pharmacist-led AMS intervention focused on duration of antibiotic treatment was feasible and had good acceptability in our setting. Cessation of audit-feedback activities was associated with immediate and sustained increases in antibiotic consumption reflecting a rapid return to baseline (pre-intervention) prescribing practices, and worse clinical outcomes (increased length of stay and in-hospital mortality). Pharmacist-led audit-feedback activities can effectively reduce antimicrobial consumption and result in better-quality care, but require organizational leadership's commitment for sustainable benefits.
低收入和中等收入国家(LMICs)抗生素的大量使用,是由实验室基础设施的严重不足以及传染病综合征根深蒂固的症状管理所推动的。几乎没有数据能说明抗菌药物管理干预措施的可实现性和影响,特别是在撒哈拉以南非洲地区。我们的目标是证明在埃塞俄比亚亚的斯亚贝巴的提库尔·安贝萨专科医院,由药剂师主导、实验室支持的干预措施的可行性,并报告与该干预措施相关的抗菌药物使用情况和临床结果。这是一项单中心前瞻性准实验研究,分两个阶段进行:(i)干预阶段(2017年11月至2018年8月),在此期间,我们对2个儿科和2个成人内科病房收治的患者的抗生素处方进行每周审核,并立即(口头和书面)反馈;(ii)干预后阶段(2018年9月至2019年1月),在此期间,我们审核抗生素处方,但不向治疗团队提供反馈。该干预措施由一个抗菌药物管理团队实施,该团队由4名临床药剂师(其中1名接受过抗菌药物管理培训)和1名感染病专家组成。我们的主要结果是抗菌药物使用情况(以每1000患者日的治疗天数(DOT)和抗生素治疗疗程的持续时间来衡量);次要结果是住院时间和院内全因死亡率。使用多变量逻辑回归模型来探索与院内全因死亡率相关的因素。我们收集了1109名个体患者的数据(干预期间707名,干预后期间402名)。头孢曲松、万古霉素、头孢吡肟、美罗培南和甲硝唑是最常用的抗生素;抗菌药物管理团队提出的建议中有96%被采纳。抗菌药物管理团队建议在干预期间54%的病例中停止抗生素治疗。一旦干预停止,抗菌药物的总使用量增加了51.6%,平均治疗时间增加了4.1天/患者。干预后阶段的平均住院时间以及粗死亡率也显著增加(住院时间:24.1天对19.8天;院内死亡14.7%对6.9%)。在调整潜在混杂因素后,死亡率的差异仍然显著。在我们的环境中,以药剂师为主导、关注抗生素治疗持续时间的抗菌药物管理干预措施是可行的,并且具有良好的可接受性。审核反馈活动的停止与抗生素消费的立即和持续增加相关,这反映了迅速恢复到基线(干预前)的处方习惯,以及更差的临床结果(住院时间增加和院内死亡率增加)。以药剂师为主导的审核反馈活动可以有效减少抗菌药物的消费,并带来更高质量的护理,但需要组织领导层的承诺才能获得可持续的益处。